Kahl S, Ofstad AP, Zinman B, Wanner C, et al. Effects of empagliflozin on markers of liver steatosis and fibrosis and their relationship to cardiorenal outcomes. Diabetes Obes Metab 2022;24:1061-1071.
PMID: 35166009